ArticleScientific reports2026
Graphene-enhanced non-Hermitian Thue-Morse metamaterial sensor exploiting exceptional point for cancer biomarker detection.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adsorption-driven Graphene Oxide SPR Biointerfaces: Coupled Thermodynamic, Kinetic, and Optical Modeling with Effective-layer Validation.Cell biochemistry and biophysics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
We present a one-dimensional photonic crystal biosensor based on a Thue-Morse quasi-periodic structure incorporating parity-time (PT) symmetry and exceptional point (EP) engineering for enhanced cancer detection. By integrating alternating porous silicon gain-loss layers with graphene nanolayers, the proposed design achieves strong optical confinement and pronounced resonance sharpening near EP conditions. A systematic parametric study identified the optimal graphene chemical potential and relaxation time as 0.408 eV and 0.5 ps, respectively, leading to a maximum sensitivity of 1054 nm/RIU and a minimum detection limit of 9.875 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.